Showing 2051-2060 of 2314 results for "".
- Optimo Medical Gets Support by Innosuisse to Enter the US Markethttps://modernod.com/news/optimo-medical-gets-support-by-innosuisse-to-enter-the-us-market/2478322/Optimo Medical announced that Optimeyes is ready to enter the US market after the FDA decided not to enforce any regulatory requirements, known as enforcement discretion. This important step forward opened the doors for Optimo Medical to receive the additional boost of a Swissnex bootcamp
- Johnson & Johnson Starts Phase 3 Study of COVID-19 Vaccine Candidatehttps://modernod.com/news/johnson-johnson-starts-phase-3-study-of-covid-19-vaccine-candidate/2478315/Johnson & Johnson launched a late-stage study of its COVID-19 vaccine candidate JNJ-78436735 following positive interim results from a phase 1/2a trial. The ENSEMBLE study will enroll up to 60,000 volunteers and will evaluate the safety and efficacy of a single vaccine dose versus placebo in
- BioNTech Snaps Up Novartis’ German Site to Expand Coronavirus Vaccine Outputhttps://modernod.com/news/biontech-snaps-up-novartis-german-site-to-expand-coronavirus-vaccine-output/2478296/BioNTech announced that it signed a share purchase agreement to acquire Novartis’ manufacturing facility in Marburg, Germany, a move it says will bolster its COVID-19 vaccine production capacity by up to 750 million doses per year, or over 60 million doses per month. BioNTech, whose Pfizer-
- AstraZeneca Kicks Off Phase 3 Study of COVID-19 Vaccine AZD1222 in the UShttps://modernod.com/news/astrazeneca-kicks-off-phase-3-study-of-covid-19-vaccine-azd1222-in-the-us/2478229/AstraZeneca announced the start of a phase 3 study in the US investigating its experimental COVID-19 vaccine AZD1222 in up to 30,000 adults aged 18 years or over. Subjects in the trial, called D8110C00001, will be randomized to receive two doses of either AZD1222 or a saline control, 4 weeks apar
- Regenxbio Announces FDA Clearance of IND for Phase 2 Trial of RGX-314 for the Treatment of DR Using Suprachoroidal Deliveryhttps://modernod.com/news/regenxbio-announces-fda-clearance-of-ind-for-phase-2-trial-of-rgx-314-for-the-treatment-of-dr-using-suprachoroidal-delivery/2478202/Regenxbio announced the clearance of the investigational new drug (IND) application by the FDA to evaluate the suprachoroidal delivery of RGX-314 in patients with diabetic retinopathy (DR). The IND is active, and Regenxbio plans to begin dosing patients in a phase 2 trial, ALTITUDE, in the second
- EU Wraps Up Advanced Talks With Moderna for COVID-19 Vaccine Supply Dealhttps://modernod.com/news/eu-wraps-up-advanced-talks-with-moderna-for-covid-19-vaccine-supply-deal/2478195/The European Commission said Monday that it concluded exploratory talks with Moderna for an initial purchase of 80 million doses of the company’s mRNA vaccine candidate against SARS-CoV-2. The contractual framework would also provide an option for EU member states to purchase an additional
- Neuroptika Completes Enrollment In Phase 2 Clinical Trial For Dry Eye Diseasehttps://modernod.com/news/neuroptika-completes-enrollment-in-phase-2-clinical-trial-for-dry-eye-disease/2478192/Neuroptika announced completion of enrollment in a phase 2 clinical controlled, double-masked trial of NRO-1 for the treatment of patients with dry eye disease. NRO-1 is a novel therapeutic with the potential to regenerate corneal nerves in ophthalmic diseases. “We are pleased to com
- Alcon Broadens US Availability of MARLO Digital Platformhttps://modernod.com/news/alcon-broadens-us-availability-of-marlo-digital-platform/2478153/Alcon announced broader US availability of its MARLO digital platform offered within independent OD practice. The platform allows patients to order, reorder and track their Alcon contact lens order online and have their lenses shipped right to their doorstep, while keeping the relationship and re
- VSY Biotechnology Launches Enova Glistening-Free Hydrophobic Acrylic IOLhttps://modernod.com/news/vsy-biotechnology-launches-enova-glistening-free-hydrophobic-acrylic-iol/2478147/VSY Biotechnology announces the launch of the Enova IOL. Enova is the first 100% glistening-free hydrophobic acrylic IOL that does not require pre-hydration or storage in saline solution, according to VSY Biotechnology. The unique composition of Enova material allows uniform hydration of s
- Russia’s Approval of Virus Vaccine Greeted With Some Alarmhttps://modernod.com/news/russias-approval-of-virus-vaccine-greeted-with-some-alarm/2478146/Russia on Tuesday became the first country to approve a coronavirus vaccine for use in tens of thousands of its citizens despite international skepticism about injections that have not completed clinical trials and were studied in only dozens of pe